Aura Biosciences rises after data from mid-stage study of cancer treatment

Aura Biosciences

12/09/2024 12:29

** Shares of cancer drug developer Aura Biosciences  AURA.O 
rise 8% to $9.80 premarket
    ** Co says mid-stage study of its treatment bel-sar showed
80% tumor control rate among patients with early-stage choroidal
melanoma, who were eligible for late-stage study
    ** Choroidal melanoma is a rare and life threatening cancer
which affects the eye
    ** The treatment also showed vision preservation in 90% of
the 10 patients, AURA says
    ** Stock up 2.4% YTD, as of last close

 (Reporting by Kashish Tandon in Bengaluru)
 ((Kashish.tandon@thomsonreuters.com))